Related Experiment Video
Updated: Jun 28, 2025
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
7.7K
Post-Radical Prostatectomy Erectile Dysfunction Assessed Using the IIEF-5 Questionnaire - A Systematic Literature
Tomasz Jurys1, Bartlomiej Burzynski2, Anna Potyka3
1Doctoral School, Faculty of Health Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland.
Summary
Erectile dysfunction (ED) is a common complication after radical prostatectomy. Recovery of erectile function typically occurs by 12 months post-surgery, with adjuvant treatments potentially enhancing outcomes.
Area of Science:
- Urology
- Andrology
- Surgical Oncology
Background:
- Erectile dysfunction (ED) is a frequent complication following radical prostatectomy (RP).
- Assessing the recovery of erectile function post-RP is crucial for patient quality of life.
- Understanding factors influencing ED recovery can guide treatment strategies.
Purpose of the Study:
- To evaluate the prevalence and recovery patterns of erectile dysfunction in men after radical prostatectomy.
- To identify potential factors and treatments that may influence erectile function recovery post-RP.
Main Methods:
- A qualitative analysis was conducted on 21 selected articles.
- Data extraction focused on studies reporting clear numerical scores from the IIEF-5 questionnaire.
Main Results:
- Erectile function recovery was observed to occur around 12 months after radical prostatectomy.
- Adjuvant treatments were suggested to potentially accelerate recovery and improve effectiveness.
- Conclusions were primarily based on studies with quantifiable IIEF-5 scores.
Conclusions:
- A significant proportion of men experience erectile dysfunction after radical prostatectomy.
- Recovery of erectile function is a gradual process, often taking up to 12 months.
- Adjuvant therapies may play a role in optimizing erectile function recovery, warranting further investigation.
Related Concept Videos
01:20Disorders of the Male Reproductive System
402
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
402
01:17Male Sexual Response: Erection & Ejaculation
2.2K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
2.2K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
150
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
150